Idelalisib plus bendamustine and rituximab improves the outcome of relapsed/refractory CLL
Andrew Zelenetz, MD, PhD from the Memorial Sloan-Kettering Cancer Center, New York, NY provides an overview of a Phase III clinical trial of idelalisib plus bendamustine and rituximab in relapsed/refr...
Author: VJHemOnc
Added: 02/10/2016
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts